Rhenman & Partners Asset Management Ab Has Trimmed Its Adamas Pharmaceuticals INC (ADMS) Position by $7.33 Million as Share Price Declined

April 17, 2018 - By Nellie Frank

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Rhenman & Partners Asset Management Ab decreased its stake in Adamas Pharmaceuticals Inc (ADMS) by 24.27% based on its latest 2017Q4 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 222,087 shares as the company’s stock declined 31.02% with the market. The institutional investor held 692,913 shares of the health care company at the end of 2017Q4, valued at $23.48M, down from 915,000 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Adamas Pharmaceuticals Inc for a number of months, seems to be less bullish one the $676.88M market cap company. The stock increased 3.61% or $0.88 during the last trading session, reaching $25.25. About 269,083 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 35.83% since April 17, 2017 and is uptrending. It has outperformed by 24.28% the S&P500.

Rhenman & Partners Asset Management Ab, which manages about $740.07 million US Long portfolio, upped its stake in Amerisourcebergen Corp (NYSE:ABC) by 94,261 shares to 174,261 shares, valued at $16.00M in 2017Q4, according to the filing. It also increased its holding in Sage Therapeutics Inc (NASDAQ:SAGE) by 54,930 shares in the quarter, for a total of 104,930 shares, and has risen its stake in Gilead Sciences Inc (NASDAQ:GILD).

Analysts await Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings on May, 8. They expect $-1.32 earnings per share, down 83.33 % or $0.60 from last year’s $-0.72 per share. After $-1.27 actual earnings per share reported by Adamas Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.94 % negative EPS growth.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 8 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamas Pharmaceuticals had 13 analyst reports since October 30, 2017 according to SRatingsIntel. Leerink Swann initiated Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Wednesday, April 4 with “Buy” rating. The stock has “Buy” rating by Noble Financial on Wednesday, November 8. Mizuho maintained the stock with “Buy” rating in Tuesday, January 23 report. On Tuesday, February 20 the stock rating was maintained by Evercore with “Buy”. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Friday, November 3 with “Buy” rating. Northland Capital initiated it with “Buy” rating and $70.0 target in Wednesday, November 29 report. As per Tuesday, January 30, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating given on Tuesday, February 20 by Mizuho. On Friday, March 9 the stock rating was maintained by Mizuho with “Buy”. The rating was maintained by Piper Jaffray with “Buy” on Thursday, February 22.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: